Conjunctivitis Clinical Trial
Official title:
The Efficacy of Punctal Dilatation With Insertion of Perforated Punctal Plugs for the Management of Acquired Punctal Stenosis Due to Allergic Conjunctivitis
Assessing efficacy of punctal dilatation with insertion of perforated punctal plugs for the management of acquired punctal stenosis due to allergic conjunctivitis in otherwise healthy patients.
The efficacy of punctal dilatation with insertion of perforated punctal plugs for the
management of acquired punctal stenosis due to allergic conjunctivitis.
Acquired punctal stenosis is a condition in which the external opening of the lacrimal
canaliculus is narrowed or occluded due to chronic inflammation and fibrosis. This condition
is a rare cause of symptomatic epiphora, but its incidence may be higher in patients with
chronic blepharitis, in those treated with various topical medications, including
antihypertensive agents, and especially in patients treated with taxanes for cancer.
The incidence of punctal stenosis is still unknown, with reported rates ranging from 8% to
54.3%, depending on setting, demographics, and probably interob¬server variability.
Nevertheless, the literature suggests that this pathology should be given special
consideration while assessing the tearing patient, because it may involve an easier surgical
solution than in patients with obstruction in the more distal lacrimal system.
Recently many oculoplastic surgeons encounter young patients (usually females) with punctual
stenosis and signs of allergic conjunctivitis but no reflex tearing. In these cases,
treatment for allergic conjunctivitis does not improve tearing. Treatment with punctoplasty
of mini- Monoka stents improve their condition for the short term. However, many patients
experience recurrence of epiphora in the long term.
There are no uniform clinical guidelines for treatment of the disease. A few methods are
currently used in the management of punctal stenosis. The most common in use are punctoplasty
or intubation with minimonoka stents. Substantial experience with these minor surgical snip
procedures would suggest giving preference to their utilization in the treatment of the
disease in our clinics.
The simplest method involves the use of perforated punctal plugs, a reversible simple
procedure that can be applied in an office setting. Silicon perforated plugs are inserted
after punctual dilatation under topical anesthesia to the lacrimal punctum in order to
maintain a patent tear drain into the nasolacrimal sac. The procedure is simple and usually
pain free. After the procedure topical steroids and antibiotics are prescribed for one week.
Plugs are extracted after a two month period in the outpatient clinic.
Unfortunately, evidence for the efficacy of the procedure for acquired punctual stenosis is
scarce. One retrospective series of 44 eyes from 26 patients treated with dilation and the
placement of a perforated punctal plug for acquired punctal stenosis, the success rate was
84.1% (37 of 44 eyes) for cessation of epiphora. The plugs were extracted after 2 months.
Most cases had partial punctal stenosis. Associated eyelid laxity was detected in 14 eyes,
and eight of them underwent a lateral tarsal strip procedure prior to plug implantation. The
mean follow-up period was 19 months. Failures were due to either restenosis or horizontal
eyelid laxity.
Another study evaluated the use of perforated punctual plugs in patients with acquired
punctual stenosis, 20 patients in total. This study showed 85% successes rate in total.
Patients where the procedure failed were usually older and were likely to have blepharitis.
Although perforated punctal plugs are an attractive non¬surgical tool in the management of
acquired punctal stenosis, the long-term results of the procedure and its role in treating
punctal stenosis requires and prospective larger clinical trials.
Study design We intend to perform a prospective clinical trial to assess the efficacy of
perforated punctual plugs in treating acquired punctual stenosis. Since patients were
previously assigned to treatment by a Crawford tube insertion, this patient group will act as
the comparison group for this study.
Adult, consenting patients will be recruited from the ophthalmology outpatient clinics in
Rabin Medical Center. Punctal plugs will be inserted in the outpatient clinics for duration
of two months.
Plug insertion will be performed under topical anesthesia after careful dilation of the
lacrimal punctum. Patients will be prescribed topical steroids and antibiotic for a one week
period following plug insertion procedure. Punctal plugs will be removed after two months
treatment period. Follow up time is intended for two years to asses both short term and long
term efficacy.
Records for patients who underwent Crawford tube insertion due to allergic conjunctivitis
will be anonymously collected from Rabin Medical Centers' database. The collected data will
be analyzed and used a comparison group for the study.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT00770315 -
Efficacy and Long-Term Safety of Ragweed (Ambrosia Artemisiifolia) Sublingual Tablet (SCH 39641) in Adults With a History of Ragweed-Induced Rhinoconjunctivitis With or Without Asthma (Study P05234)
|
Phase 3 | |
Completed |
NCT00783198 -
Efficacy and Long-Term Safety of Ragweed (Ambrosia Artemisiifolia) Sublingual Tablet in Adults With a History of Ragweed-Induced Rhinoconjunctivitis With or Without Asthma (Study P05233)(COMPLETED)
|
Phase 2/Phase 3 | |
Recruiting |
NCT06229379 -
The Effects of a Large Language Model on Clinical Questioning Skills
|
N/A | |
Not yet recruiting |
NCT03631108 -
Feasibility Study and Preliminary Application Study on Iris OCTA
|
||
Completed |
NCT01028027 -
Loteprednol and Tobramycin Versus Tobramycin and Dexamethasone, in the Treatment of Blepharokeratoconjunctivitis
|
Phase 3 | |
Completed |
NCT00978029 -
Safety Study of Ragweed Allergy Immunotherapy Tablet in Subjects 50 Years of Age and Older (Study P06081)
|
Phase 2 | |
Completed |
NCT00550550 -
Efficacy and Safety of Grass Sublingual Tablet in Children and Adolescents (P05239 AM3)(COMPLETED)
|
Phase 3 | |
Completed |
NCT00562159 -
Efficacy and Safety of Grass Sublingual Tablet in Adults (P05238 AM3)(COMPLETED)
|
Phase 3 | |
Withdrawn |
NCT02795273 -
Efficacy and Safety of Grass-SPIRE Registration Study
|
Phase 2/Phase 3 | |
Not yet recruiting |
NCT01600365 -
Evaluate the Use of Ganciclovir Gel 0.3% for the Treatment of Conjunctivitis Caused by Adenovirus
|
Phase 3 | |
Completed |
NCT00567918 -
Phase III, Long-Term, Open-Label, Extension Study of 0.1% Tacrolimus(FK506) Ophthalmic Suspension in Patients With Vernal Keratoconjunctivitis
|
Phase 3 | |
Completed |
NCT04374656 -
Prevalence of SARS-CoV-2 in Conjunctival Swab Samples Among Patients With Conjunctivitis During the COVID-19 Pandemic
|
||
Completed |
NCT03753893 -
Ocular Manifestations in Rheumatic Diseases
|
||
Completed |
NCT02472223 -
Reducing Adenoviral Patient Infected Days
|
N/A | |
Completed |
NCT00001734 -
Screening for NEI Clinical Studies
|
N/A | |
Completed |
NCT00623701 -
Efficacy and Safety From a High-dosed Sublingual Grass Pollen Preparation
|
Phase 3 | |
Completed |
NCT00581542 -
Moxifloxacin vs. Polytrim for Conjunctivitis
|
Phase 4 | |
Completed |
NCT04287608 -
Observational Study of Conjunctivitis in the Setting of DUPIXENT® Treatment for Atopic Dermatitis
|
||
Completed |
NCT04984941 -
Evaluation of the Role of IgE Responses to Der p 1 and Der p 2 in Chinese House Dust Mite-Allergic Patients
|
||
Completed |
NCT01385371 -
A Study of SCH 697243 in Participants With Grass Pollen Allergy Symptoms, With or Without Asthma (P08067)
|
Phase 3 |